113 related articles for article (PubMed ID: 30017114)
1. New somatostatin-drug conjugates for effective targeting pancreatic cancer.
Ragozin E; Hesin A; Bazylevich A; Tuchinsky H; Bovina A; Shekhter Zahavi T; Oron-Herman M; Kostenich G; Firer MA; Rubinek T; Wolf I; Luboshits G; Sherman MY; Gellerman G
Bioorg Med Chem; 2018 Jul; 26(13):3825-3836. PubMed ID: 30017114
[TBL] [Abstract][Full Text] [Related]
2. Synthesis, drug release, and biological evaluation of new anticancer drug-bioconjugates containing somatostatin backbone cyclic analog as a targeting moiety.
Redko B; Ragozin E; Andreii B; Helena T; Amnon A; Talia SZ; Mor OH; Genady K; Gary G
Biopolymers; 2015 Nov; 104(6):743-52. PubMed ID: 26058565
[TBL] [Abstract][Full Text] [Related]
3. Application of human pancreatic carcinoid BON cells for receptor-targeted drug development.
Sun L; Morris LM; Luo J; Mackey LV; Leslie JS; Franko-Tobin LG; Fuselier JA; LePage KT; Coy DH
J Drug Target; 2011 Sep; 19(8):666-74. PubMed ID: 21083509
[TBL] [Abstract][Full Text] [Related]
4. Investigation of cancer cell lines for peptide receptor-targeted drug development.
Sun L; Luo J; Mackey LV; Morris LM; Franko-Tobin LG; LePage KT; Coy DH
J Drug Target; 2011 Sep; 19(8):719-30. PubMed ID: 21830941
[TBL] [Abstract][Full Text] [Related]
5. Multifunctional nanoparticles as somatostatin receptor-targeting delivery system of polyaniline and methotrexate for combined chemo-photothermal therapy.
Nguyen HT; Phung CD; Thapa RK; Pham TT; Tran TH; Jeong JH; Ku SK; Choi HG; Yong CS; Kim JO
Acta Biomater; 2018 Mar; 68():154-167. PubMed ID: 29292170
[TBL] [Abstract][Full Text] [Related]
6. Lanreotide-conjugated PEG-DSPE micelles: an efficient nanocarrier targeting to somatostatin receptor positive tumors.
Zheng N; Dai W; Zhang H; Wang X; Wang J; Zhang X; Wang K; Li J; Zhang Q
J Drug Target; 2015 Jan; 23(1):67-78. PubMed ID: 25366085
[TBL] [Abstract][Full Text] [Related]
7. A novel lanreotide-encoded micelle system targets paclitaxel to the tumors with overexpression of somatostatin receptors.
Zheng N; Dai W; Du W; Zhang H; Lei L; Zhang H; Wang X; Wang J; Zhang X; Gao J; Zhang Q
Mol Pharm; 2012 May; 9(5):1175-88. PubMed ID: 22435704
[TBL] [Abstract][Full Text] [Related]
8. Somatostatin receptor-targeted anti-cancer therapy.
Sun LC; Coy DH
Curr Drug Deliv; 2011 Jan; 8(1):2-10. PubMed ID: 21034425
[TBL] [Abstract][Full Text] [Related]
9. Targeting of cytotoxic somatostatin analog AN-238 to somatostatin receptor subtypes 5 and/or 3 in experimental pancreatic cancers.
Szepeshazi K; Schally AV; Halmos G; Sun B; Hebert F; Csernus B; Nagy A
Clin Cancer Res; 2001 Sep; 7(9):2854-61. PubMed ID: 11555603
[TBL] [Abstract][Full Text] [Related]
10. Effects of camptothecin conjugated to a somatostatin analog vector on growth of tumor cell lines in culture and related tumors in rodents.
Sun L; Fuselier JA; Coy DH
Drug Deliv; 2004; 11(4):231-8. PubMed ID: 15371104
[TBL] [Abstract][Full Text] [Related]
11. Nanotechnology-Based Strategy for Enhancing Therapeutic Efficacy in Pancreatic Cancer: Receptor-Targeted Drug Delivery by Somatostatin Analog.
Gu X; Majumder J; Taratula O; Kuzmov A; Garbuzenko O; Pogrebnyak N; Minko T
Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791582
[TBL] [Abstract][Full Text] [Related]
12. Targeted delivery of chemotherapy using HSP90 inhibitor drug conjugates is highly active against pancreatic cancer models.
Bobrov E; Skobeleva N; Restifo D; Beglyarova N; Cai KQ; Handorf E; Campbell K; Proia DA; Khazak V; Golemis EA; Astsaturov I
Oncotarget; 2017 Jan; 8(3):4399-4409. PubMed ID: 27779106
[TBL] [Abstract][Full Text] [Related]
13. Effects of chemotherapeutic agents on expression of somatostatin receptors in pancreatic tumor cells.
Fueger BJ; Hamilton G; Raderer M; Pangerl T; Traub T; Angelberger P; Baumgartner G; Dudczak R; Virgolini I
J Nucl Med; 2001 Dec; 42(12):1856-62. PubMed ID: 11752085
[TBL] [Abstract][Full Text] [Related]
14. Valproic acid induces NET cell growth arrest and enhances tumor suppression of the receptor-targeted peptide-drug conjugate via activating somatostatin receptor type II.
Sun L; Qian Q; Sun G; Mackey LV; Fuselier JA; Coy DH; Yu CY
J Drug Target; 2016; 24(2):169-77. PubMed ID: 26211366
[TBL] [Abstract][Full Text] [Related]
15. Radioiodine and 211At-labeled guanidinomethyl halobenzoyl octreotate conjugates: potential peptide radiotherapeutics for somatostatin receptor-positive cancers.
Vaidyanathan G; Boskovitz A; Shankar S; Zalutsky MR
Peptides; 2004 Dec; 25(12):2087-97. PubMed ID: 15572196
[TBL] [Abstract][Full Text] [Related]
16. Camptothecin-somatostatin conjugates inhibit the growth of small cell lung cancer cells.
Moody TW; Fuselier J; Coy DH; Mantey S; Pradhan T; Nakagawa T; Jensen RT
Peptides; 2005 Sep; 26(9):1560-6. PubMed ID: 16112393
[TBL] [Abstract][Full Text] [Related]
17. Anti-metastatic potential of somatostatin analog SOM230: Indirect pharmacological targeting of pancreatic cancer-associated fibroblasts.
Moatassim-Billah S; Duluc C; Samain R; Jean C; Perraud A; Decaup E; Cassant-Sourdy S; Bakri Y; Selves J; Schmid H; Martineau Y; Mathonnet M; Pyronnet S; Bousquet C
Oncotarget; 2016 Jul; 7(27):41584-41598. PubMed ID: 27177087
[TBL] [Abstract][Full Text] [Related]
18. Somatostatin receptors in pituitary and development of somatostatin receptor subtype-selective analogs.
Shimon I
Endocrine; 2003 Apr; 20(3):265-9. PubMed ID: 12721506
[TBL] [Abstract][Full Text] [Related]
19. KE108-conjugated unimolecular micelles loaded with a novel HDAC inhibitor thailandepsin-A for targeted neuroendocrine cancer therapy.
Chen G; Jaskula-Sztul R; Harrison A; Dammalapati A; Xu W; Cheng Y; Chen H; Gong S
Biomaterials; 2016 Aug; 97():22-33. PubMed ID: 27156249
[TBL] [Abstract][Full Text] [Related]
20. Identification of somatostatin receptor subtypes and an implication for the efficacy of somatostatin analogue SMS 201-995 in treatment of human endocrine tumors.
Kubota A; Yamada Y; Kagimoto S; Shimatsu A; Imamura M; Tsuda K; Imura H; Seino S; Seino Y
J Clin Invest; 1994 Mar; 93(3):1321-5. PubMed ID: 8132773
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
